Cyclin-A1 (385-395)

Cyclin-A1 (385-395) is a synthetic peptide corresponding to amino acids 385 through 395 of the human Cyclin-A1 protein, a member of the cyclin family that plays a pivotal role in cell cycle regulation. As a functional fragment of a cell cycle-related protein, this peptide is of significant interest in biochemical and molecular biology research focused on cell division, checkpoint control, and cyclin-dependent kinase (CDK) interactions. The sequence encompasses a region implicated in protein-protein interactions and regulatory mechanisms essential to the progression of mitosis and meiosis, making it a valuable tool for dissecting the molecular underpinnings of cell proliferation and differentiation.

Peptide mapping: Cyclin-A1 (385-395) serves as a reference standard for peptide mapping experiments, enabling researchers to characterize and confirm the presence of Cyclin-A1-derived sequences in complex biological samples. By employing this synthetic peptide in mass spectrometry or chromatographic analyses, investigators can validate the identity of peptides generated by enzymatic digestion, facilitating the study of post-translational modifications, proteolytic processing, and protein turnover associated with Cyclin-A1 in various cellular contexts.

Protein interaction studies: The defined sequence of this peptide fragment provides a precise tool for probing protein-protein interactions involving Cyclin-A1. It can be used in affinity-based assays, such as pull-downs or surface plasmon resonance, to investigate binding partners, elucidate interaction motifs, or map domains responsible for regulatory associations with CDKs and other cell cycle effectors. Such studies contribute to a deeper understanding of how Cyclin-A1 coordinates cell cycle events through its molecular interfaces.

Antibody production and validation: As an immunogenic fragment, the Cyclin-A1 (385-395) peptide is suitable for generating sequence-specific antibodies. Polyclonal or monoclonal antibodies raised against this region can be employed to selectively detect Cyclin-A1 in immunoassays, including Western blotting, immunoprecipitation, or immunofluorescence. Using a well-defined sequence ensures high specificity and facilitates the discrimination of Cyclin-A1 from related cyclin family members, supporting accurate protein localization and quantification in research samples.

Kinase substrate assays: The peptide can function as a substrate or competitive inhibitor in kinase assays designed to study Cyclin-A1-associated CDK activity. By incorporating this fragment into in vitro phosphorylation experiments, researchers can assess kinase specificity, monitor phosphorylation events, and screen for modulators of Cyclin-A1/CDK complexes. These applications are instrumental in dissecting the regulatory networks that govern cell cycle transitions and identifying novel points of intervention for cell proliferation control.

Epitope mapping and structural analysis: Cyclin-A1 (385-395) is valuable for epitope mapping studies, enabling the identification of antibody binding sites or conformational epitopes within the Cyclin-A1 protein. Additionally, the synthetic peptide can be used in structural biology approaches, such as NMR spectroscopy or crystallography, to investigate the conformational properties of this region and its role in mediating molecular recognition. Such insights are essential for unraveling the structural determinants of Cyclin-A1 function and its integration into larger protein complexes.

1. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

2. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

4. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

5. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide